MilliporeSigma Opens China's First BioReliance® End-to-End Biodevelopment Center in Shanghai

  MilliporeSigma Opens China's First BioReliance® End-to-End Biodevelopment
                              Center in Shanghai

  Canada NewsWire

  BILLERICA, Mass., Sept. 22, 2017

- Company's first end-to-end center outside of Europe

- Accelerates clinical development from molecule to commercial production

BILLERICA, Mass., Sept. 22, 2017 /CNW/ -- MilliporeSigma today announced the
opening of its first BioReliance® End-to-End Biodevelopment Center in the Asia
Pacific (APAC) region. Located in Shanghai, China, the center will provide a
full range of process development capabilities and services, including cell
line development, upstream and downstream process development and non-GMP
clinical production.

"Our new BioReliance ^® End-to-End Biodevelopment Center will host small-scale
drug manufacturers working on early-phase clinical trials," said Udit Batra,
CEO, MilliporeSigma. "MilliporeSigma has 30 years of process development
experience and a track record of delivering robust clinical production process
and clinical material within nine to 12 months. We look forward to advancing
scientific discovery and innovation in China and beyond.

The Shanghai center is designed to meet the specific needs of customers in the
APAC region. Staffed by local process scientists and engineers, the center
will provide an integrated suite of services for biopharmaceutical companies
in China and across APAC to accelerate clinical drug development from molecule
to commercial production. Customers will get full support, not only with
process development or production, but also with regulatory, quality and

"MilliporeSigma is a leading solutions provider," said Dr. Chengbin Wu,
founder and CEO, EpimAb Biotherapeutics, a privately held start-up company
dedicated to generating novel bi-specific antibody therapeutics in oncology
and immune-oncology based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
"The opening of this center will provide biopharma and emerging biotech
companies like us access to the latest technologies and experienced
scientists, helping us in accelerating our drug development and providing more
affordable medicine to patients."

MilliporeSigma's end-to-end global team has a track record of executing nearly
240 large molecule projects, ranging in scale from three to 2,000-liters.
Early-stage companies with limited resources and infrastructure can benefit
from MilliporeSigma's expertise and experience in process development and GMP
clinical manufacturing to advance their early clinical development programs.
Additionally, MilliporeSigma's end-to-end approach can facilitate and
accelerate scaling, process and analytical method validation and technical
transfer of an entire process to a customer-designated location.

MilliporeSigma's end-to-end offering delivers important benefits and addresses
key challenges for biopharmaceutical companies at all stages of molecule
development and commercialization in any geography.

MilliporeSigma's BioReliance ^® End-to-End Biodevelopment Center in Martillac,
France, is a fully operational, single-use, GMP facility for manufacturing
clinical-stage batches. Equipped with a full suite of MilliporeSigma
technologies, including the 2000-liter single-use Mobius ^® bioreactor,
Martillac offers biopharma companies a complete solution to support their
clinical development programs.

MilliporeSigma's BioReliance ^® End-to-End Biodevelopment Center in
Burlington, Massachusetts, USA will provide a full range of process
development capabilities and services. This includes cell line development
services and both upstream and downstream process development, as well as
non-GMP clinical production.

This new investment in China marks another milestone for MilliporeSigma in one
of Asia's most dynamic biotech markets. In November 2016, the company
announced a $300 million production value chain investment in Nantong,
dedicated to both the production of pharmaceuticals on China's Essential Drug
List and the manufacture of a range of innovative products and services for
the pharma, biopharma and life sciences industries.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at
the same time they become available on the EMD Group website. In case you are
a resident of the U.S. or Canada please go to to
register again for your online subscription of this service as our newly
introduced geo-targeting requires new links in the email. You may later change
your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany The Life
Science business of Merck KGaA, Darmstadt, Germany, which operates as
MilliporeSigma in the U.S. and Canada, has 20,000 employees and 65
manufacturing sites worldwide, with a portfolio of more than 300,000 products
enabling scientific discovery. Udit Batra is the global chief executive
officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of
Sigma-Aldrich in November 2015, creating a leader in the $125 billion global
life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and
top-quality high-tech products in healthcare, life science and performance
materials. The company has six businesses – Biopharmaceuticals, Consumer
Health, Allergopharma, Biosimilars, Life Science and Performance Materials –
and generated sales of €15 billion in 2016. Around 50,000 employees work in 66
countries to improve the quality of life for patients, to foster the success
of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and
chemical company – since 1668, the company has stood for innovation, business
success and responsible entrepreneurship. Holding an approximately 70 percent
interest, the founding family remains the majority owner of the company to
this day. The company holds the global rights to the name and the trademark
"Merck" internationally except for the United States and Canada, where the
company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.



View original content with multimedia:

SOURCE MilliporeSigma

View original content with multimedia:

Karen Tiano +1 978 495 0093

For further information: Karen Tiano +1 978 495 0093

CO: MilliporeSigma

ST: China

Press spacebar to pause and continue. Press esc to stop.